Monte Rosa Therapeutics, Inc. (GLUE)
Nasdaq: GLUE · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2020
Who owns Monte Rosa Therapeutics, Inc.
As filed with the SECHolders of 5% or more
8
T. Rowe Price Associates, Inc. holds 10.5% of COMMON STOCK, as its SCHEDULE 13G/A filed Jul 8, 2026 says.
Directors and officers
14
report now, of 22 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.
Holders of 5% or moreshare of the class, as filed
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Jul 8, 2026 · COMMON STOCK · 7.5% in Nov 14, 2025
Baker Bros. Advisors LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · 6.7% in Feb 17, 2026
Adam Goulburn
SCHEDULE 13G/A · filed Apr 22, 2026 · Common Stock, par value $0.0001 per share · 8.7% in Jan 21, 2026
New Enterprise Associates 17, L.P.
SCHEDULE 13D/A · filed Jul 6, 2026 · Common Stock, par value $0.0001 per share · 9.7% in Mar 19, 2026
Bvf Partners L P/il
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 5.9% in Feb 17, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Feb 4, 2025 · Common Stock
Chen Yu
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · 7.2% in Oct 17, 2025
Vestal Point Capital, LP
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share
The Vanguard Group
SCHEDULE 13G/A · filed Oct 31, 2025 · Common Stock · reported falling below 5%, from 5.13% in Jan 30, 2025
Montanova Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common stock, par value $0.0001 per share · reported falling below 5%, from 5.5% in Apr 16, 2025
Versant Venture Capital VI, L.P.
SCHEDULE 13D/A · filed Jan 9, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.1% in Nov 12, 2025
Fmr LLC
SCHEDULE 13G/A · filed Jun 6, 2025 · COMMON STOCK · reported falling below 5%
Avoro Capital Advisors LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.1% in Aug 14, 2025
What GLUE reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 17, 2026.
Insider tradesForm 4
37sales
0purchases
21sales on a scheduled plan
8people selling
$4.1Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 6, 2025 to Oct 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 42 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Janku Filip | Chief Medical Officer | 6 | $1.4M | 4 | 0 | $0 |
| Warmuth Markus | President & CEO | 10 | $1.0M | 7 | 0 | $0 |
| Dunn Edmund | Principal Accounting Officer | 4 | $500,000 | 0 | 0 | $0 |
| Townson Sharon | Chief Scientific Officer | 6 | $400,000 | 5 | 0 | $0 |
| Manning Anthony M. | director | 2 | $400,000 | 0 | 0 | $0 |
| Champoux Jennifer | Chief Operating Officer | 6 | $300,000 | 5 | 0 | $0 |
| Nickson Philip | Chief Business & Legal Officer | 2 | $200,000 | 0 | 0 | $0 |
| Bowen Matthew | Principal Accounting Officer | 1 | $0 | 0 | 0 | $0 |